Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Herceptin Prescribers: Medical Oncologists(?)

Council Members in this Study Group: 75

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

Ben Ebrahimi, MD
Consultant
Medical Consulting Firm of Dr. Ben Ebrahimi

Ben Ebrahimi, MD, is Director of Clinical Trials at Wilshire Oncology Medical Group. Dr. Ebrahimi oversees clinical trials in various tumor types and treats a variety of cancer patients including lung, breast, colorectal, and lymphomas. These clinical trials include biological agents as well as targeted...

Rossana Berardi, MD
Consultant Medical Oncologist
UniversitĂ  Politecnica delle Marche

Rossana Berardi, MD, is a Researcher and Lecturer - Consultant Medical Oncologist in the Department of Medical Oncology at the Universita Politecnica delle Marche, Italy, since November 2005. She is involved in clinical research and GCP trials on the treatment of solid tumors in particular on gastrointestinal...

Michael Grossbard, MD
Professor of Clinical Medicine
Columbia University College of Physicians and Surgeons

Michael Grossbard, MD, is a Professor of Clinical Medicine at Columbia University College of Physicians and Surgeons and the Chief of Hematology-Oncology at St. Luke's-Roosevelt Hospital and Beth Israel Medical Center in New York City. His clinical research is in monoclonal antibodies, non-Hodgkin's...

Sujith Kalmadi
Staff Physician
Ironwood Cancer & Research Center

Sujith Kalmadi, MD, is a Staff Physician at the Ironwood Cancer and Research Center in Phoenix, Arizona. Dr. Kalmadi has previously worked as a Clinical Assistant Professor at Baylor school of Medicine in Houston, Texas, and at the Lerner School of Medicine at the Cleveland Clinic, Ohio. He has interest...

Taral Patel, MD, Oncologist, Mid Ohio Oncology Hematology Inc.Taral Patel, MD
Oncologist
Mid Ohio Oncology Hematology Inc.

Taral Patel, MD, is an Oncologist in private practice with Mid Ohio Oncology-Hematology, Inc. He treats patients with both cancer and blood disorders. Dr. Patel has been a principal investigator for multiple clinical trials in colon cancer, lung cancer, lymphoma, and growth factor. He has been on the...

Christian Singer, MD, CEO & Founder, Hellmann & MoedlingerChristian Singer, MD
CEO & Founder
Hellmann & Moedlinger

Christian Singer, MD, MPH is a Professor of Obstetrics & Gynecology at the University of Vienna Medical Center, Austria since November 1997. He is also the Founder & CEO of Hellmann & Moedlinger, a public health consulting firm in United Kingdom since 2003. Dr. Singer is the Director of the Program...

Pedro Gascon, MD, PhD
Director of Medical Oncology
Hospital Clinic Barcelona

Pedro Gascon, MD, PhD, is the Director of Medical Oncology and Scientific Coordinator of the Hematology-Oncology Department at Hospital Clinic Barcelona, Spain. Dr. Gascon is board certified in Internal Medicine, Hematology, and Medical Oncology, and his main clinical interests include colorectal cancer,...

Haitham Al-Okk, MD, Assistant Clinical Professor - Hematology-Oncology, Mahr Cancer CenterHaitham Al-Okk, MD
Assistant Clinical Professor - Hematology-Oncology
Mahr Cancer Center

Haitham Al-Okk, MD, is a Specialist in Hematology-Oncology at Graves-Gilbert Cancer Clinic, a multi-specialty medical group in Kentucky. Dr. Al-Okk is board certified in Internal Medicine and Medical Oncology, and fellowship trained in Hematology-Oncology. He specializes in lung, breast, and colorectal...

GLG NewsSMAnalyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
By Michael Grossbard, MD, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons
Analysis of: Scientists recommend 'black box' for Avastin | www.fiercepharma.com

In pooled data from 8000 patients across 15 studies, the risk of blood clots was increased by 12% in patients receiving Avastin.

By Michael Grossbard, MD, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons
Analysis of: Amgen Told to Reword Drug Label | www.nytimes.com

The FDA required Amgen to revise the label for Procrit and Aranesp so that these agents are not used until a patient's hemoglobin drops below 10 or in the setting of potentially curative therapy.

By Michael Grossbard, MD, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons
Analysis of: Transparency in Healthcare | www.hospitalimpact.org

The author argues that transparency in healthcare will be an important step forward for the consumer.

By Michael Grossbard, MD, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons

Avastin improves survival in colon cancer and lung cancer and improves progression free survival in breast cancer- clinically meaningful outcomes.  Yet these gains are of relatively short duration and the cost of Avastin is significant- 50,000 to 100,000 dollars per year.

By Michael Grossbard, MD, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons
Analysis of: UK Says Kidney Cancer Drugs Are Too Pricey | www.pharmalot.com

NICE has stated that the cost of several novel agents for the treatment of renal cell cancer including Sutent, Torisel, Avastin, and Nexavar exceeds the benefit when assessed by quality adjusted life years (QALY) gained from the therapies.

View All GLG News by members of this Study Group

Most Common Company Types:

  • Academic Medical Center/Hospital or Clinic
  • Office Based Private Practice or Clinic
  • Non-Academic Community Hospital or Clinic
  • Academic Institution*

Most Common Job Types:

  • Physician - Attending Physician
  • Owner
  • Physician - Director
  • Partner
  • Physician - Division Head

GLG's 850+ Clients Include:

Fortune 500®  companies
40 of the leading 50  global mutual funds
15 of the leading 20  global banks
8 of the leading 10  global private equity firms
5 of the top 10  AmLaw firms

Analytics


Generated at 2009-01-08T19:00:17.880